[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-marrow-transplant-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-marrow-transplant-complications":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,96,123,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100561447","diagnostic-refinement-and-educational-approaches-in-managing-bone-marrow-transplantation-100561447",false,"NCT06590285","Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation","Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation (DREAM-BMT)","DREAM-BMT","Inclusion Criteria:\n\n* Male or female patients aged 18 or older at the time of study informed consent.\n* Have plan to undergo alloHSCT from any donor source using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative and reduced intensity conditioning are eligible.\n* Patients have access to digital device capable of downloading study app\n* Patients able to read study documents and able to complete informed consent within the study app\n\nExclusion Criteria:\n\n* Failed prior alloHSCT within the past 6 months","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, phase I\u002FII, open-label study will investigate the efficacy and safety of an educational sleep intervention vs standard of care in adults undergoing alloHSCT. The randomization target in this pilot phase is 60 patients.",[27,28],"GVHD","Bone Marrow Transplant Complications","RECRUITING","2026-04-03",{"date":32,"type":33},"2026-04-09","ACTUAL",{"date":35,"type":33},"2026-04-02",{"date":37,"type":21},"2033-11-01",{"name":39,"class":40},"Scripps Health","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100557660","a-novel-digital-application-shift-to-improve-outcomes-for-hematopoietic-stem-cell-transplant-survivors-100557660","NCT06541002","A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","Multi-Site Randomized Controlled Trial of a Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","SHIFT","Inclusion Criteria:\n\n* Adult patients (\\> 18 years) who underwent autologous or allogeneic HCT \\> three months prior to study enrollment\n* Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions\n\nExclusion Criteria:\n\n* Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.\n* Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.\n* Patients with relapsed disease requiring treatment.",{"count":51,"type":21},300,[24],"This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.",[55,56,28],"Sexual Dysfunction","Stem Cell Transplant Complications","2026-03-17",{"date":59,"type":33},"2026-03-19",{"date":61,"type":33},"2025-01-27",{"date":63,"type":21},"2030-04-30",{"name":65,"class":40},"Massachusetts General Hospital",3,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100586099","multidisciplinary-intervention-for-adults-with-chronic-graft-versus-host-disease-100586099","NCT06910969","Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease","Multi-Site Randomized Controlled Trial of A Multidisciplinary Intervention for Adults With Chronic Graft Versus Host Disease","HORIZONS","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) who have undergone allogeneic HCT\n* Have moderate to severe cGVHD based on patient-report\n* Have ability to participate in English or Spanish language group telehealth intervention.\n\nExclusion Criteria:\n\n* Patients with mild cGVHD based on their self-report.\n* Patients with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.\n* Patients with active relapsed disease requiring therapy.",{"count":76,"type":21},350,[24],"The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for hematopoietic stem cell transplant (HSCT) survivors living with chronic graft-versus host disease, and to identify critical facilitators and barriers for HORIZONS implementation and adoption.",[28,80],"Graft-versus-Host Disease",[82,83,84,85,86],"neoplasms","hematologic diseases","neoplasms by site","hematologic neoplasms","graft-versus-host disease","2026-03-01",{"date":89,"type":33},"2026-03-03",{"date":91,"type":33},"2025-08-13",{"date":93,"type":21},"2030-02-01",{"name":65,"class":40},2,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":66},"100552361","bmt-care-psychosocial-intervention-for-transplant-caregivers-100552361","NCT06472089","BMT-CARE: Psychosocial Intervention for Transplant Caregivers","Multimodal Psychosocial Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation","BMT-CARE","Caregiver Inclusion Criteria:\n\n* Adult caregivers (≥18 years) relative or friend of a patient identified as living with them or having in-person contact with them at least twice a week.\n* Caregiver of a patient receiving allogeneic or autologous HCT for the treatment of cancer.\n* Ability to read and respond to survey questions in English, Spanish or with minimal assistance from an interpreter.\n\nCaregiver Exclusion Criteria:\n\n* Caregivers of patients undergoing HCT for a benign hematologic condition or undergoing outpatient HCT.\n* Caregivers with a major untreated psychiatric or cognitive condition which the treating oncology clinicians believes interferes with the capacity to provide informed consent.\n* Caregivers of patients who have already undergone HCT within the past 5 years\n\nPatient Inclusion Criteria:\n\n* Adult patients (≥18 years) with a hematologic malignancy and planned admission for autologous or allogeneic HCT.\n* Ability to respond to questions in English, Spanish, or with minimal assistance from an interpreter.",{"count":105,"type":21},800,[24],"The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and to identify critical facilitators and barriers for BMT-CARE implementation and adoption.",[28,109],"Hematologic Malignancy",[111,112,113,114],"Neoplasms by Site","Hematologic Diseases","Neoplasms","Hematologic Neoplasms","2025-10-13",{"date":117,"type":33},"2025-10-15",{"date":119,"type":33},"2025-01-10",{"date":121,"type":21},"2029-02",{"name":65,"class":40},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":141,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":41},"100548112","genetics-in-the-progression-of-nephropathies-100548112","NCT06416761","Genetics in the Progression of Nephropathies","The Genetic Contribution to Progression of Kidney Disease","Inclusion Criteria:\n\n. presence of specific renal disease\n\nExclusion Criteria:\n\n* to be evaluated in the different sub-protocols",{"count":131,"type":21},10000,"OBSERVATIONAL","This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to:\n\n* AKI\n* CKD\n* Hypertension\n* ADPKD\n* CKD-MBD\n* Patients with decompensated heart failure undergoing either medical or surgery therapy\n* Patients with hematologic cancer exposed to chemotherapeutic agents or undergoing allogeneic bone marrow transplantation\n* glomerular diseases",[135,136,137,138,139,140,109,28],"AKI","CKD","Ckd-Mbd","CKD (Chronic Kidney Disease) Stage 5D","ADPKD","Hypertension",[142,143,144,145,146,147],"genetic in hypertensive kidney disease","salt intake in BP control and CKD progression","genetic in CKD","endogenous Ouabain as marker of AKI","protein intake restriction in CKD progression","hypertension in allogenic bone marrow transplantation","2024-05-11",{"date":150,"type":33},"2024-05-16",{"date":152,"type":33},"2006-05-19",{"date":154,"type":21},"2041-05-19",{"name":156,"class":40},"Ospedale San Raffaele",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":41},"100348556","phase-2-post-transplant-cyclophosphamide-in-matched-unrelated-donor-stem-cell-transplantation-for-hematological-malignancies-100348556","NCT03818334","Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies","Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Men and Women of Any Age\n* Indication for an HSCT without matched sibling donor\n* Have a matched unrelated donor (HLA 10 x 10 or 9 x 10)\n* Hematological malignancy\n\nExclusion Criteria:\n\n* Acute leukemias not in complete response (that is \\> 5% blast in the bone marrow)\n* Chemorefractory lymphoproliferative disease\n* Active uncontrolled infection\n* HCT-CI \\> 3\n* Severe organic disfunction (heart ejection fraction \\\u003C 45%, glomerular filtration rate \\\u003C 50 mL.hour, pulmonary DLCO \\\u003C 50%)\n* Previous allogeneic bone marrow transplantation\n* Contraindication to cyclophosphamide or ATG","1 Year","75 Years",{"count":167,"type":21},50,[169,170],"PHASE2","PHASE3","This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).",[28,173,174,175,176],"Graft Versus Host Disease","Infection Viral","Engraft Failure","Immunologic Suppression",[178,179,180],"Bone Marrow Transplantation","Hematological Malignancies","Post-Cy","2019-01-31",{"date":183,"type":33},"2019-02-01",{"date":185,"type":33},"2018-11-06",{"date":187,"type":21},"2026-11-01",{"name":189,"class":40},"Hospital Israelita Albert Einstein"]